Department of Respiratory Medicine, North Tyneside General Hospital, North Shields, UK.
Thorax. 2012 Feb;67(2):117-21. doi: 10.1136/thoraxjnl-2011-200332. Epub 2011 Sep 6.
Rates of mortality and readmission are high in patients hospitalised with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). In this population, the prognostic value of the Medical Research Council Dyspnoea Scale (MRCD) is uncertain, and an extended MRCD (eMRCD) scale has been proposed to improve its utility. Coexistent pneumonia is common and, although the CURB-65 prediction tool is used, its discriminatory value has not been reported.
Clinical and demographic data were collected on consecutive patients hospitalised with AECOPD. The relationship of stable-state dyspnoea severity to in-hospital mortality and 28-day readmission was assessed. The discriminatory value of CURB-65, MRCD and eMRCD, in the prediction of in-hospital mortality, was assessed and compared.
920 patients were recruited. 10.4% died in-hospital and 19.1% of the 824 survivors were readmitted within 28 days of discharge. During their stable state prior to admission, 34.2% of patients were too breathless to leave the house. Mortality was significantly higher in pneumonic than in non-pneumonic exacerbations (20.1% vs 5.8%, p<0.001). eMRCD was a significantly better discriminator than either CURB-65 or the traditional MRCD scale for predicting in-hospital mortality, and was a stronger prognostic tool than CURB-65 in the subgroup of patients with pneumonic AECOPD.
The severity of dyspnoea in the stable state predicts important clinical outcomes in patients hospitalised with AECOPD. The eMRCD scale identifies a subgroup of patients at a particularly high risk of in-hospital mortality and is a better predictor of mortality risk than CURB-65 in exacerbations complicated by pneumonia.
慢性阻塞性肺疾病急性加重(AECOPD)患者的死亡率和再入院率较高。在这一人群中,医学研究委员会呼吸困难量表(MRCD)的预后价值尚不确定,因此提出了扩展 MRCD(eMRCD)量表以提高其效用。同时存在肺炎的情况很常见,尽管使用 CURB-65 预测工具,但尚未报告其区分能力。
连续收集 AECOPD 住院患者的临床和人口统计学数据。评估稳定状态下呼吸困难严重程度与住院内死亡率和 28 天内再入院的关系。评估并比较 CURB-65、MRCD 和 eMRCD 在预测住院内死亡率方面的区分能力。
共纳入 920 例患者。住院内 10.4%的患者死亡,824 例幸存者中有 19.1%在出院后 28 天内再次入院。在入院前的稳定状态下,34.2%的患者呼吸困难严重,无法离开家。肺炎性加重组的死亡率明显高于非肺炎性加重组(20.1%比 5.8%,p<0.001)。与 CURB-65 或传统的 MRCD 量表相比,eMRCD 量表在预测住院内死亡率方面是更好的区分器,在肺炎性 AECOPD 患者亚组中,eMRCD 量表是比 CURB-65 更强的预后工具。
在 AECOPD 住院患者中,稳定状态下呼吸困难的严重程度可预测重要的临床结局。eMRCD 量表确定了一组特别高的住院内死亡率风险的患者,并且在伴有肺炎的加重中,eMRCD 量表是死亡率风险的更好预测因子。